MARKET

TRVN

TRVN

Trevena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.251
+0.061
+2.76%
Opening 13:10 02/24 EST
OPEN
2.200
PREV CLOSE
2.190
HIGH
2.290
LOW
2.180
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
3.680
52 WEEK LOW
0.4600
MARKET CAP
353.40M
P/E (TTM)
-10.0784
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10 Annual SVB Lee...
GlobeNewswire · 1d ago
Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
PHILADELPHIA, Feb 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic...
GlobeNewswire · 5d ago
8-K: TREVENA INC
(EDGAR Online via COMTEX) -- 0001429560 false 0001429560 2021-02-11 2021-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/12 05:22
BRIEF-Trevena Inc - ICL Now Expects That Primary Completion Date Of Trv027 Study Will Be In First Half Of 2021
reuters.com · 02/11 22:56
Trevena says low incidence of respiratory depression linked to oliceridine
Announcing the publication of a new analysis of respiratory safety data from a Phase 3 multi-site ‘real-world’ safety study, Trevena (TRVN) says there is a low incidence of respiratory depression
Seekingalpha · 01/28 12:56
BRIEF-Trevena Inc Announces Publication Highlighting Olinvyk Respiratory Safety Data In High-Risk Patients In Pain & Therapy
reuters.com · 01/28 12:15
Trevena, Inc. Announces Publication Highlighting OLINVYK(TM) Respiratory Safety Data in High-Risk Patients in Pain & Therapy
--
GlobeNewswire · 01/28 12:00
Trevena, Inc. Announces Publication Highlighting OLINVYK(TM) Respiratory Safety Data in High-Risk Patients in Pain & Therapy
CHESTERBROOK, Pa., Jan 28, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection...
GlobeNewswire · 01/28 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TRVN. Analyze the recent business situations of Trevena through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TRVN stock price target is 5.25 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 109
Institutional Holdings: 23.71M
% Owned: 15.10%
Shares Outstanding: 157.03M
TypeInstitutionsShares
Increased
24
3.62M
New
33
1.76M
Decreased
9
598.00K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+1.25%
Key Executives
Chairman/Independent Director
Leon Moulder
President/Chief Executive Officer/Director
Carrie Bourdow
Chief Financial Officer/Senior Vice President
Barry Shin
Senior Vice President/Chief Compliance Officer
Scott Applebaum
Senior Vice President
Mark Demitrack
Senior Vice President
Robert Yoder
Director
Maxine Gowen
Independent Director
Scott Braunstein
Independent Director
Michael Dougherty
Independent Director
Julie McHugh
Independent Director
Jake Nunn
Independent Director
Anne Phillips
Independent Director
Barbara Yanni
  • Dividends
  • Splits
  • Insider Activity
No Data
About TRVN
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Webull offers kinds of Trevena Inc stock information, including NASDAQ:TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.